Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
Accelerating drug development for neuroblastoma
An international forum of leading scientists from the UK, Europe and USA, funded by national charity Neuroblastoma UK, prioritises drug development and strategies for new treatment trials for children with neuroblastoma.
In the September edition of European Journal of Cancer, Dr Lucas Moreno from Vall d’Hebron Hospital, Barcelona, and a team of international scientific and clinical experts published an agreed list of genetic targets and drugs that should be advanced for early-phase paediatric clinical trials, following the second Neuroblastoma New Drug Development Strategy (NDDS) forum.
SIOPEN High-Risk Neuroblastoma Clinical Trial 2 to open in the UK in 2021
Neuroblastoma UK with Solving Kids’ Cancer has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK. The trial is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study, enabling a series of important randomised questions to be answered within the overall framework of the trial.
Press release: Charities fund new clinical trial to help children with cancer
Neuroblastoma UK and Solving Kids Cancer have awarded a grant to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study.
Committed to our cause
The current and rapidly evolving situation with coronavirus presents significant challenges for the research community and every sector.
The coronavirus and government guidelines are already having a significant impact on neuroblastoma research, now and in the future. These changes, whilst temporary and very much supported by all of us at Neuroblastoma UK, may affect the pace and progress of vital neuroblastoma research.
Developing personalised treatment for children with neuroblastoma
In 2019, we awarded £236,141 to Dr Suzanne Turner at the University of Cambridge, as part our 2019 research grant round.
Here we meet Dr Turner and find out more about her three year research project aimed at improving the effectiveness of ALK inhibitors for children with neuroblastoma.
International Women's Day 2020
International Women's Day (8th March 2020) is a global day celebrating the achievements of women.
Thanks to your support, we fund amazing researchers working to improve treatments for neuroblastoma. Today we celebrate those female scientists who work tirelessly to help more children with neuroblastoma.
Can a keto diet enhance therapy for neuroblastoma?
In 2019, we awarded nearly £5,000 to Prof Robert Falconer and Xiaoxiao Guo at the University of Bradford.
This research grant enabled them to explore the potential for a ketogenic diet to enhance neuroblastoma therapy. Let’s find out more.
Understanding how neuroblastoma develops
With Children’s Cancer and Leukaemia Group (CCLG), we awarded £72,656 to Dr Anestis Tsakiridis at the University of Sheffield.
The team are working to understand how human trunk neural crest cells become cancerous. This research could lead to further investigations to stop neuroblastoma cells from developing.
Dr Tsakiridis shares his motivations, why team work matters and tells us more about his exciting work.
Dr Zoë Walters’ research into combination therapies
In 2019, as part of our Small Grants programme, we awarded £5,000 to Dr Zoë Walters at the University of Southampton.
Dr Walters tells us more about her research into the treatment of neuroblastoma, why she is passionate about cancer research and how she hopes to make a difference to children with neuroblastoma.
Camels, antibodies and cancer cells
We have joined forces with the Bradley Lowery Foundation to provide funding of £153,369 to the Laman group.
The team hope to develop a new approach in targeting the protein N-Myc, a well known cause of some of the worst neuroblastomas. Dr Laman answers our questions about her role, her team and how camels may help get us a step closer to a cure for neuroblastoma.